Caribou Biosciences Inc (CRBU)vsEli Lilly and Company (LLY)
CRBU
Caribou Biosciences Inc
$0.42
-4.90%
HEALTHCARE · Cap: $55.64M
LLY
Eli Lilly and Company
$1,411.53
-0.46%
HEALTHCARE · Cap: $1.26T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 861504% more annual revenue ($86.46B vs $10.04M). LLY leads profitability with a 31.9% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 74/100 (B).
CRBU
Avoid26
out of 100
Grade: F
LLY
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+30.0%
Fair Value
$2.27
Current Price
$0.42
$1.85 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 7.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CRBU
The strongest argument for CRBU centers on Price/Book, Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : CRBU
The primary concerns for CRBU are EPS Growth, Market Cap, Profit Margin.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
CRBU profiles as a value stock while LLY is a growth play — different risk/reward profiles.
CRBU carries more volatility with a beta of 2.31 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 26/100), backed by strong 31.9% margins and 38.6% revenue growth. CRBU offers better value entry with a 30.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Caribou Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in genome editing through its proprietary CRISPR technology, aimed at developing transformative therapies for genetic disorders and oncology. With a robust and diversified pipeline addressing significant unmet medical needs, the company is well-positioned to lead advancements in precision medicine. Caribou's strategic collaborations and unwavering commitment to research excellence underpin its mission to revolutionize treatment paradigms and improve patient outcomes, establishing its foothold as a key player in the biopharmaceutical sector.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?